BioCentury
ARTICLE | Company News

Alliance Pharma, Beacon Pharma sales and marketing update

September 19, 2011 7:00 AM UTC

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired marketing rights in the U.K. to six dermatology products from Beacon for £2.4 million ($3.8 million) in cash. Alliance said the products, which include five prescription brands and one medical device, had sales of about £2 million ($3.3 million) for the 12 months ending April 30. The deal includes severe acne drug Rizuderm isotretinoin. ...